Lupin, Natco receive US FDA approval for Eribulin Mesylate Injection EP News Bureau Jun 3, 2026 ANDA approval covers Eribulin Mesylate Injection, the bioequivalent of Halaven Injection, for metastatic breast cancer and…
Glenmark Pharmaceuticals to launch Eribulin Mesylate Injection, 1mg/2Ml (0.5 mg/mL) single-dose… EP News Bureau Sep 2, 2025 Glenmark Pharmaceuticals, a research‐led, global pharmaceutical company has announced the launch of Eribulin Mesylate Injection, 1…
